Alliance A221805 Trial Finds Duloxetine Ineffective at Preventing Chemotherapy-Induced Nerve Damage

The Alliance A221805 trial finds duloxetine is no more effective than a placebo at preventing peripheral neuropathy in colorectal cancer patients.

By: AXL Media

Published: Apr 8, 2026, 11:03 AM EDT

Source: Information for this report was sourced from Alliance for Clinical Trials in Oncology

The Challenge of Preventive Neurology in Oncology

Oxaliplatin-induced peripheral neuropathy (OIPN) remains one of the most debilitating side effects of standard colorectal cancer treatment, affecting approximately 94% of patients. Characterized by persistent numbness, tingling, and acute pain in the extremities, the condition frequently leads to chemotherapy dose reductions, which can compromise the efficacy of the underlying cancer treatment. While duloxetine has been an established tool for managing chronic neuropathic pain once it has developed, researchers sought to determine if early intervention could arrest the damage at its cellular origin. The Alliance A221805 trial, however, has provided definitive evidence that the drug does not function as a prophylactic agent.

A Rigorous Multi-Center Evaluation of Prophylactic Efficacy

The Alliance A221805 trial stands as the largest randomized, double-blind study to date focused specifically on the prevention of OIPN. Enrolling 199 adults with stage II or III colorectal cancer across 73 clinical sites in the United States, the study utilized a three-arm design to evaluate 30 mg and 60 mg daily doses of duloxetine against a placebo. Participants began their regimen on the same day as their first oxaliplatin dose and continued the medication for 17 weeks. By using validated patient-reported outcomes measured several weeks after the completion of chemotherapy, the study aimed to capture the real-world functional impact of the drug on the early stages of nerve damage.

Statistical Failure and the Confounding Impact of Placebo Response

The primary endpoint of the study—a composite measure of the severity and onset of sensory symptoms—revealed no clinically meaningful difference between the treatment groups. In the placebo group, 68% of participants met the criteria for a favorable response (minimal to no neuropathy), compared to 65.2% in the 30 mg duloxetine group and 66% in the 60 mg group. Dr. Ellen M. Lavoie Smith, the study chair, noted that high "prevention" rates were observed across all three groups, suggesting a strong placebo response that may have confounded the results. This phenomenon provides new insights for future clinical trial designs, particularly regarding the high expectations patients often have for symptom-control medications.